These substances are related to the DEA’s interest in researching hallucinogenic controlled products for clinical tests and research. The DEA asserts that it wants to support the regulated trials of schedule 1 substances, so increasing the production quota explains why this move is essential. The DEA also wants to research the requirements for manufacturing new drugs and the kind of impact marijuana has on the body. These steps are taken to work towards the Food and Drug Administration’s possibilities to approve a new drug.
Slapwoods is announcing its first-ever official collaboration with DJ Screw, the late Houston legend whose…
It could be so easy to believe that cannabis culture is something that has been…
Modern cultivation techniques and spiritual practices collide with Pink Boost Goddess on our next Legendary…
Animal rescuers and advocacy groups say dogs living on Skid Row are suffering from neglect,…
This article originally appeared in High Times’ 50th Anniversary print issue. It is an excerpt…
How Montana built a legal cannabis market from a thin medical marijuana law, federal raids,…